【摘要】 目的:探讨金芪降糖片对糖尿病患者血浆ET-1和sICAM-1水平的影响及临床应用价值。方法:金芪降糖片和降糖类西药同时服用治疗糖尿病,并与只服西药治疗组进行比较。采用酶联免疫法检测两组患者治疗前后血浆中血管内皮细胞活性因子ET-1和sICAM-1水平,同时观察血糖和血脂、HbAlc等各项指标的变化。结果:金芪组治疗后血糖和血脂、HbAlc均有显著变化(P<0.05),对照组仅血糖有明显变化(P<0.05);金芪组治疗后ET-1和sICAM-1均显著降低,分别为P<0.05和P<0.01,对照组两者水平皆无明显变化(P>0.05)。结论:金芪降糖片通过降低糖尿病患者血浆中ET-1和sICAM-1水平,从而保护患者的血管内皮细胞,在西药常规治疗糖尿病的基础上,再加以中药辨证施治,可以提高临床对糖尿病的疗效。更多还原

【Abstract】 Objective To investigate the clinical beneficial effect of Jiqi hypoglycemic tablet on lowering the plasma ET-1 and soluble intercellular adhesion molecule-1 (sICAM-1) levels in patients with DM2. Methods Plasma ET-1 and sICAM-1 levels were determined with ELISA in 30 patients with DM2 randomly selected to be treated with conventional western only medicine and 30 other DM2 patients selected to be treated with additional Jiqi hypoglycemic tablet both before and after 3 months’ treatment. The blood sugar level, HbAlc percentage and lipid test (cholesterol, triglyceride, HDL, LDL) were also examined. Results Blood sugar levels decreased significantly after 3 months’ treatment in both groups. However, favorable changes of levels of other parameters (HbAlc, TC, TG, HDL, LDL, ET-1, sICAM-1) were demonstrated only in the patients treated with combined Jiqi hypoglycemic tablet and conventional western medicine (P<0.05 or P<0.01). Conclusion Additional Jiqi hypoglycemic tablet might be desirable for the treatment of DM2 patients, especially due to the possible protection on vascular endothelium through lowering of the plasma ET-1 and sICAM-1 levels.更多还原